Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
| Descrizione | Lingua | Dimensioni | Downloads | |
|---|---|---|---|---|
 |
IT | 965 kB | 903 |
Regolamento delegato (UE) 2022/699 della Commissione del 3 maggio 2022 che modifica il regolamento (UE) 2021/821 del Parlamento europeo e del Consiglio escludendo la...
House of Commons Library - BRIEFING PAPER Number CBP 8403, 1 May 2020
What is REACH?
REACH is the main EU legislation for the regulation of chemicals in the EU (th...
ID 18835 | 26.01.2023 / In allegato
L'arsenico ha uno spiccato effetto neurotossico, letale ad alte dosi. A dosi più basse, l’esposizione prolunga...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024